Abstract
Purpose The results of SUV quantification for prediction of histopathological response in patients with oesophageal carcinoma show high variations with different accuracy. However, the routine use of a full dynamic PET is limited because of long acquisition times. We tested a shortened acquisition protocol for quantitative PET to overcome that limitation. Material and methods 13 patients with histopathologically proven oesophageal adenocarcinoma underwent a combined dynamic and static 18 F-FDG PET/CT including CT tumour perfusion (Siemens, Biograph mCT). Dynamic PET (listmode) was acquired for 60 min resulting in 38 frames from 10 to 600 sec duration for the full dynamic dataset and 2 frames each with 600 sec duration (20-30 min and 50-60 min p.i.) for dual time point PET (DTP). We evaluated the metabolic rate Ki using different models: 2-compartment irreversible model (Fit), Patlak plot and DTP (van den Hoff et al). The CT tumour perfusion protocol included the parameters blood flow, blood volume and permeability. Results
Highlights
Dynamic PET was acquired for 60 min resulting in 38 frames from 10 to 600 sec duration for the full dynamic dataset and 2 frames each with 600 sec duration (20-30 min and 50-60 min p.i.) for dual time point PET (DTP)
We evaluated the metabolic rate Ki using different models: 2-compartment irreversible model (Fit), Patlak plot and DTP
The metabolic rate Ki could be reliably reproduced independent of the analytical model; we observed only slight variations of Ki with respect to the analytical model: -4,9% (Patlak vs.Fit), -10% (DTP vs.Fit) and -5,1% (DTP vs. Patlak)
Summary
Therapy response assessment with quantitative PET: evaluation of a shortened acquisition protocol with dynamic PET/CT C Pfannenberg*, SC Schüle, C Brendle, J Schwenck, K Nikolaou, C La Fougère, J Kupferschläger From International Cancer Imaging Society (ICIS) 14th Annual Teaching Course Heidelberg, Germany. Purpose The results of SUV quantification for prediction of histopathological response in patients with oesophageal carcinoma show high variations with different accuracy.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
